221 related articles for article (PubMed ID: 9744508)
1. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
3. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
[TBL] [Abstract][Full Text] [Related]
5. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
6. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein.
Schlichtholz B; Trédaniel J; Lubin R; Zalcman G; Hirsch A; Soussi T
Br J Cancer; 1994 May; 69(5):809-16. PubMed ID: 7514026
[TBL] [Abstract][Full Text] [Related]
7. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression.
Guinee DG; Travis WD; Trivers GE; De Benedetti VM; Cawley H; Welsh JA; Bennett WP; Jett J; Colby TV; Tazelaar H
Carcinogenesis; 1995 May; 16(5):993-1002. PubMed ID: 7767998
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
[TBL] [Abstract][Full Text] [Related]
9. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
10. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
12. Fine tuning of epitopic dominance induced by lung cancer on the IgG response to bovine betalactoglobulin: towards a paraneoplastic immune marker.
Michils A; Lambert JP; Yernault JC; Fabry V; Gossart B; Duchateau J
Cancer; 1996 Feb; 77(4):657-64. PubMed ID: 8616757
[TBL] [Abstract][Full Text] [Related]
13. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
[TBL] [Abstract][Full Text] [Related]
14. Anti-elastin antibodies in patients with lung cancer.
Gmiński J; Mykała-Cieśla J; Machalski M; Drózdz M
Immunol Lett; 1992 Jul; 33(2):211-5. PubMed ID: 1332926
[TBL] [Abstract][Full Text] [Related]
15. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
16. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis.
Kawai T; Suzuki M; Kono S; Shinomiya N; Rokutanda M; Takagi K; Ogata T; Tamai S
Cancer; 1994 Nov; 74(9):2468-75. PubMed ID: 7923002
[TBL] [Abstract][Full Text] [Related]
17. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
18. The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
Bergström S; Dreilich M; Wagenius G; Brattström D; Larsson A; Hesselius P; Bergqvist M
In Vivo; 2004; 18(5):615-20. PubMed ID: 15523902
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibodies as early markers of lung cancer.
Lubin R; Zalcman G; Bouchet L; Trédanel J; Legros Y; Cazals D; Hirsch A; Soussi T
Nat Med; 1995 Jul; 1(7):701-2. PubMed ID: 7585154
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
Neri M; Betta P; Marroni P; Filiberti R; Cafferata M; Mereu C; Ivaldi G; Montanaro F; Puntoni R; Paganuzzi M
Lung Cancer; 2003 Feb; 39(2):165-72. PubMed ID: 12581569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
